Brain Imaging Services for Parkinson's Disease (PD) Research

Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease, and typical symptoms include resting tremors, and slowed movement. Ultimately, the inability to control motor functions can lead to severe disability in patients. One of the recognized markers of Parkinson's disease is the presence of Lewy bodies, which consist primarily of the easily aggregated neuronal protein alpha-synuclein. Brain imaging provides a non-invasive means of observing and evaluating structural and functional changes in a patient's brain which plays an important role in Parkinson's disease research.

Services Overview

CD BioSciences offers brain imaging services for parkinson's disease research to better understand the disease's whole-brain changes through animal models, non-invasive imaging techniques, and histologic imaging analysis. Through brain imaging, it is possible to study the pathophysiologic processes of Parkinson's disease, and patterns of brain activity, and help clients evaluate the effectiveness of treatments and develop new therapeutic strategies.

Brain Imaging Services for Parkinson's Disease (PD) Research

Animal models

CD BioSciences offers various experimental animal models for research on Parkinson's disease. Combined with imaging technology, these models can help researchers better understand the pathogenesis of Parkinson's disease, evaluate drug efficacy, and find potential treatments. Our experimental animal models of PD include the following, but are not limited to:

• Neurological injury models
• 6-hydroxydopamine (6-OHDA) model
• Trichlorophenyltetrahydropyran (MPTP) model
• Lipopolysaccharide (LPS) induction model
• MFB damage model
• Transgenic models based on PD-related genes
• LRRK2 transgenic model
• α-SYN transgenic model
• Parkin transgenic model

Histologic imaging services for Parkinson's disease

CD BioSciences provides histologic imaging services for Parkinson's disease to help clients observe and analyze brain tissue sections from animal models of Parkinson's disease, which can be used to study pathological changes in the disease and related protein expression.

• Use HE staining technique to analyze tissue sections of the substantia nigra region by light microscopy to observe changes in the morphology and number of neurons in the substantia nigra region.
• The following features of nigral neurons can be assessed, including
• Nucleus morphology
• Intensity of cytoplasmic staining
• Cell arrangement
• Neuronal number changes

Biomarker imaging services for Parkinson's disease

Utilizing non-invasive imaging techniques can observe and quantify biological markers of Parkinson's disease in mouse models, mainly including:

• α-synuclein: abnormal aggregation of α-synuclein is one of the important factors in the pathological changes of Parkinson's disease, forming Lewy vesicles.
• DJ-1 (PARK7): associated with the mechanism and pathological process of Parkinson's disease, mutation or abnormal expression is associated with hereditary Parkinson's disease and may lead to impaired protein function.
• Dopamine: Parkinson's disease is caused by a decrease in dopamine in brain cells in the substantia nigra region, and dopamine concentration and metabolic activity can be used as biomarkers.
• Other potential markers: tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), vitamin D, insulin-like growth factor 1, miRNAs, and urates, etc.

Neuroimaging test services

Through non-invasive imaging techniques (such as MRI, PET), we quantitatively and qualitatively evaluate morphological changes in substantia nigra neurons and defects in striatal dopamine function, providing customers with accurate data and image analysis.

CD BioSciences has a professional team and advanced imaging equipment. The whole process of brain imaging services for Parkinson's disease (PD) research is operated by experienced technicians to ensure the accuracy of the experiment. If you have any needs, please feel free to contact us.

*If your organization requires the signing of a confidentiality agreement, please contact us by email.

Please note: Our services can only be used for research purposes. Do not use in diagnostic or therapeutic procedures!